Slide 1: Q1 2025 Earnings Call
Q1 2025 Earnings Call May 7, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements During the course of this presentation and question-and-answer session, there will be forward-looking statements regarding future events, performance, plans, expectations and other projections, including those relating to: • The launch, commercial opportunity and therapeut
Slide 3: Introductory Remarks
Introductory Remarks Dawn Bir Interim President and Chief Executive Officer 3
Slide 4: Welcome and Introduction
Welcome and Introduction DAWN JOSEPH EID, JIM MICHELLE BIR M.D. ZIEGLER ROBERTSON Interim President, Executive Vice President, Executive Vice President, Executive Vice President, Chief Executive Officer Research and Development Chief Commercial Officer Chief Financial Officer and Treasurer 4
Slide 5: Agenda
Agenda Commercial & Medical Affairs Updates: U.S. RYTELO commercial success is top corporate priority ◦ Investments made to bolster launch and drive RYTELO demand ◦ Goal: Return to steady growth and maximize potential ◦ Approach to EU commercialization IMpactMF Phase 3 clinical trial evaluating RYTE
Slide 6: Commercial Updates
Commercial Updates Jim Ziegler EVP, Chief Commercial Officer 6
Slide 7: RYTELO LR-MDS U.S. Market Opportunity with Significant Potential
RYTELO LR-MDS U.S. Market Opportunity with Significant Potential Estimated 2025 U.S. RYTELO Total Addressable LR-MDS Patient Population ∼ 16,800 ∼45% 1L patients expected to progress to 2L treatment in 2025 ESA Eligible: ~13,400 ~15,400 ∼59% ∼ 7,600 2L patients expected U.S. RYTELO total to progress
Slide 8: Commercial Strategy and Plan of Action
Commercial Strategy and Plan of Action #1 Increase HCP RYTELO #2 Improve HCP Prescribing #3 Generate KOL Brand Awareness Confidence & Clarity Support & Advocacy Refined prescriber targeting Social & digital New regional marketing roles Increased field brand campaigns Executive engagements
Slide 9: Accounts Treating Eligible LR-MDS Patients Identified
Accounts Treating Eligible LR-MDS Patients Identified Refined Commercial Targeting to Reach Accounts Treating the Majority of Diagnosed Patients >10,000 HCPs treat diagnosed MDS patients in the U.S. ~6,300 HCPs treat ~80% of the diagnosed MDS patients ~1,300 HCPs treat ~50% of the diagnosed MDS pati
Slide 10: Recent RYTELO Performance Indicators are Encouraging
Recent RYTELO Performance Indicators are Encouraging ~900 ~25% ~10% 85% Ordering accounts of RYTELO new demand increase of covered lives since approval, with patient starts in 1st current 4 weeks under plans with ~300 new accounts and 2nd line2 (ending 04/25/25) favorable since January 20251 vs prio
Slide 11: Key Considerations in EU4 Launch Planning
Key Considerations in EU4 Launch Planning • RYTELO approved for the treatment of certain adults with transfusion-dependent anemia due to lower-risk MDS • Positive COMP opinion maintains RYTELO’s orphan drug designation in the EU expected 10 years market exclusivity Anticipate commercialization Opt
Slide 12: Medical Updates
Medical Updates Joseph Eid, M.D. EVP, Research and Development 12
Slide 13: Medical Affairs Plan of Action
Medical Affairs Plan of Action #1 Increase HCP RYTELO #2 Improve HCP Prescribing #3 Generate KOL Brand Awareness Confidence & Clarity Support & Advocacy Increased Medical Liaison 2025 ASCO Abstract Acceptances Executive/KOL Engagements Headcount-Alignment with 2025 EHA Abstract Acceptances
Slide 14: Telomerase Inhibition Represents a Novel MOA with Unique Benefits
Telomerase Inhibition Represents a Novel MOA with Unique Benefits RYTELO MOA and Phase 2 Data Support our Confidence in the MF Indication Telomerase is increased Imetelstat binds to Apoptosis of malignant cells in malignant cells telomerase, inhibiting and recovery of effective its activity hematopo
Slide 15: IMpactMF Trial 85% Enrolled Interim Analysis Anticipated 2H 2026
IMpactMF Trial 85% Enrolled ClinicalTrials.gov Identifier: NCT04576156 Interim Analysis Anticipated 2H 2026* Our confidence in the MF indication is supported by the results of the Phase 2 MF study, where we saw a strong signal regarding prolonged survival and decreased bone marrow fibrosis after tre
Slide 16: Financial Results
Financial Results Michelle Robertson EVP, Chief Financial Officer 16
Slide 17: Financial Overview
Financial Overview Cash Balance Net Revenue Operating Expenses ~$457.5M $39.4M $56.3M Cash and marketable Q1 2025 net Q1 2025 total OpEx securities as of 3/31/25 product revenue $115.9M $270M to $285M total net product revenue 2025 expected since launch (June 2024) OpEx range 17
Slide 18: Closing Remarks
Closing Remarks Dawn Bir Interim President and Chief Executive Officer 18
Slide 19: Thank You
Thank You U.S. RYTELO commercial success is #1 corporate priority EU commercialization plans MF interim data analysis anticipated 2H 2026* *These projections are based on expectations about event rates (deaths) and enrollment, which can change 19 over time and may differ from our current expectation
Slide 20: Q&A
Q&A 20
Slide 21: Thank you!
Thank you! Contact: Investor Relations investor@geron.com 21